AT
Aegle Therapeutics Corp
SEC filingBiotechnology · Woburn, MA
Amount raised$2.3Msold at filing
Total offering$2.3M
Investors in the raise17count reported to the SEC
FiledAug 28, 2026first sale Aug 4, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Evangelos BadiavasDirector
Scott BraunsteinDirector
Shelley HartmanExecutive Officer, Director
Leon MoulderDirector
Executive officers, directors and promoters as listed on the Form D.